The device is in interrelation with other systems that comprise lipid mediators like prostaglandins leukotrienes systems. A definite antagonist, chemical or synergic effect of non-steroidal anti-inflammatory drugs cannabinoid organizations was not yet proven. Goal. The present study tried to review the existent information on NSAIDS cannabinoid system interactions. Practices and results. A bibliographic research in Medline, Scirus, Embase was built using as keywords cannabinoid, Letrozole CGS 20267 nonsteroidal anti inflammatory drugs, aspirin, ibuprofen, flurbiprofen, diclofenac, indomethacin, acetaminophen, coxibs, antinociceptive, antinociception, analgesia. Discussions. A systematization of the outcomes focusing on the NSAIDs drugs interaction with the system was introduced. Out of all the materials examined in the present evaluation, acetaminophen was learned the most regarding its interferences with the system, mainly due to contradictory results. Conclusions. Some NSAIDs have additional impacts to the system either by inhibiting Plastid fatty acid amide hydrolase or by inhibiting a possible intracellular transporter of endocannabinoids. All the NSAIDs that inhibit COX2 could influence the cannabinoid system must be possible important degradative pathway for anandamide and 2 arachidonoyl glycerol might contain COX 2. One of the causes for the range of experimental results presented could be due to pharmacokinetic elements, based on the route of administration and the amount. Only in 1964 when Ganoi and Mechoulam recognized 9 tetrahydrocannabinol being the primary psychotropic agent from Cannabis sativa the researches in the field of cannabinoids gain scale. Several efforts to find the substrate of analgesic and psychotropic effects of 9 THC were made. Anastrozole ic50 The discovery of cannabinoid receptors and endogenous cannabinoids came to exist twenty years later. The two main endocannabinoids discovered were, to be able, 2 arachidonoyl glycerol and anandamide. Cannabinoid process is made up of complex variety of receptors, materials with agonist/antagonist qualities for those receptors, biosynthetic machineries and mechanisms for cellular uptake and degradation for endocannabinoids. It may represent a brand new target for medications that produce analgesia, attenuation of nausea and nausea in cancer chemotherapy, reduction of intraocular pressure, appetite stimulation in losing syndromes, respite from muscle spasms/spasticity in multiple sclerosis and decreased intestinal motility. The results tend to be associated with adverse reactions like changes in cognition and memory, dysphoria/euphoria, and sedation. The endocannabinoid process is in interrelation with other systems that comprise fat mediators like prostaglandins/leukotrienes systems. Nowadays it’s well known that cyclo-oxygenase type-2 actions both on resulting prostaglandins, arachidonic acid and other eicosanoids, and on prostaglandin glycerol esters, resulting prostamides and endocannabinoids.